Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 33

Sort by

Sort Order Select

Journal Articles

Cullin-1 Controls The Clinical and Cellular response to Bortezomib Through NF-Kb Pathway Activation In Myeloma

James Driscoll, MD, PhD, Elias J. Anaissie, MD, Sajjeev Jagannathan, BS

Blood (2013) 122 (21): 4445.

https://doi.org/10.1182/blood.V122.21.4445.4445

Published: 2013

Journal Articles

Autophagy Is Uncoupled From ATG5-Dependent Apoptosis in Cells Resistant To Proteasome Inhibition

James Driscoll, MD, PhD, Elias J. Anaissie, MD, Sajjeev Jagannathan, BS

Blood (2013) 122 (21): 4448.

https://doi.org/10.1182/blood.V122.21.4448.4448

Published: 2013

Journal Articles

Chemotherapy-Induced Oral Mucositis: 11 SNPs Implicated In GWAS Of 972 Patients With Multiple Myeloma

Elizabeth Ann Coleman, PhD, Jeannette Y Lee, Ph.D., Stephen Erickson, Ph.D, Julia Goodwin, PhD, Marjorie Beggs, PhD, Naveen Sanathkumar, MD, Daohong Zhou, MD, Kent McKelvey, MD, Vinay Raj, Ph.D., Senu Apewokin, MD, Owen Stephens, Ph.D., Carol Enderlin, Ph.D., Annette Juul Vangsted, MD, Patty Reed, MS, Elias J. Anaissie, MD

Blood (2013) 122 (21): 3316.

https://doi.org/10.1182/blood.V122.21.3316.3316

Published: 2013

Journal Articles

Weight Loss, CD-34 Cell Dose and Melphalan Dose More Than 5 Mg/Kg Independently Predicted Severe Complications in Patients with Myeloma Undergoing Transplant.

Stephen Medlin, DO, FACP, Stephen Erickson, Ph.D, Elias J. Anaissie, MD

Blood (2012) 120 (21): 3145.

https://doi.org/10.1182/blood.V120.21.3145.3145

Published: 2012

Journal Articles

Deregulated Cellular Iron Metabolism Factors Mediate Iron Overload in Myeloma Cells and Osteoclasts, and Promote Myeloma Growth and Bone Disease,

Rakesh Bam, Wen Ling, MS, Sharmin Khan, MS, Sathisha Upparahalli Venkateshaiah, PhD, Xin Li, PhD, Frits van Rhee, MD, PhD, Bijay Nair, MD, Saad Usmani, MD, FACP, Bart Barlogie, MD, PhD, John D Shaughnessy, Jr., PhD, Joshua Epstein, DSc, Elias J. Anaissie, MD, Shmuel Yaccoby, PhD

Blood (2011) 118 (21): 3941.

https://doi.org/10.1182/blood.V118.21.3941.3941

Published: 2011

Journal Articles

Low Expression of Nuclear Glucocorticoid Receptor Gene NR3C1 in Newly Diagnosed Myeloma Correlates with Inferior Prognosis and Is Rescued by Thalidomide

Christoph Heuck, MD, Jackie Szymonifka, Qing Zhang, PhD, Saad Usmani, MD, FACP, Bijay Nair, MD, Sarah Waheed, MD, Yazan Alsayed, MD, Frits van Rhee, MD, PhD, Elias J. Anaissie, MD, Antje Hoering, PhD, John Crowley, PhD, John D Shaughnessy, Jr., PhD, Bart Barlogie, MD, PhD

Blood (2011) 118 (21): 988.

https://doi.org/10.1182/blood.V118.21.988.988

Published: 2011

Journal Articles

Jumping Translocations 1q12 Contribute to Copy Number (CN) Alterations in Multiple Myeloma (MM): Unexpected Focal Amplifications of Receptor Chromosomes (RC)

Jeffrey Sawyer, Erming Tian, PhD, John D. Shaughnessy, Jr., PhD, Janet Lukacs, Regina Lichti Binz, Edward Thomas, Gael Sammartino, Charles Swanson, Christoph Heuck, MD, Yazan Alsayed, MD, Elias J. Anaissie, MD, Bijay Nair, MD, Sarah Waheed, MD, Saad Usmani, MD, FACP, Frits van Rhee, MD, PhD, Bart Barlogie, MD, Ph.D

Blood (2011) 118 (21): 298.

https://doi.org/10.1182/blood.V118.21.298.298

Published: 2011

Journal Articles

The Immature Reticulocyte Fraction Predicts Marrow Recovery and Can Obviate the Need for Bone Marrow Examination in Persistently Neutropenic Cancer Patients

Sajjad Haider, MD, Lakshmikanth Katragadda, MD, Jameel Muzaffar, MD, Monica Grazziutti, MD, Muhammad R Akbar, MD, Michele H. Cottler-Fox, MD, Bart Barlogie, MD, Ph.D, Elias J. Anaissie, MD

Blood (2011) 118 (21): 4526.

https://doi.org/10.1182/blood.V118.21.4526.4526

Published: 2011

Journal Articles

Pacmed Salvage Therapy for Advanced High-Risk Multiple Myeloma (AHRMM)

Yazan Alsayed, MD, Sarah Waheed, MD, Jackie Szymonifka, Bijay Nair, MD, MPH, Saad Usmani, MD, Frits van Rhee, MD, PhD, Elias J. Anaissie, MD, Monica Grazziutti, Antje Hoering, PhD, Bart Barlogie, MD, PhD

Blood (2010) 116 (21): 1969.

https://doi.org/10.1182/blood.V116.21.1969.1969

Published: 2010

Journal Articles

Total Therapy 2 (TT2) for Multiple Myeloma (MM): Contributions to Survival Outcomes of Dosing of Thalidomide (T), Dexamethasone (D) and Interferon (I) Maintenance Components.

Frits van Rhee, MD, PhD, Bart Barlogie, MD, PhD, Jackie Szymonifka, Elias J. Anaissie, MD, Bijay Nair, MD, MPH, Sarah Waheed, MD, Yazan Alsayed, MD, Nathan Petty, John Shaughnessy, Jr, PhD, Antje Hoering, PhD, John Crowley, PhD

Blood (2010) 116 (21): 1356.

https://doi.org/10.1182/blood.V116.21.1356.1356

Published: 2010

Journal Articles

Comparing Toxicities and Survival Outcomes with Total Therapy 4 (TT4) for 70-Gene (R70)-Defined Low-Risk Multiple Myeloma (MM) to Results Obtained with Total Therapy 3 Protocols TT3A and TT3B

Elias J. Anaissie, MD, Frits van Rhee, MD, PhD, Antje Hoering, PhD, Sarah Waheed, MD, Yazan Alsayed, MD, Nathan Petty, Monica Grazziutti, John Crowley, PhD, Bart Barlogie, MD, PhD

Blood (2010) 116 (21): 368.

https://doi.org/10.1182/blood.V116.21.368.368

Published: 2010

Journal Articles

Super (S)-Beam for Advanced and Refractory Multiple Myeloma (ARMM)

Sarah Waheed, MD, Bijay Nair, MD, MPH, Yazan Alsayed, MD, Monica Grazziutti, Elias J. Anaissie, MD, Frits van Rhee, MD, PhD, Nathan Petty, Doug Steward, Jackie Szymonifka, Antje Hoering, PhD, John Crowley, PhD, Bart Barlogie, MD, PhD

Blood (2010) 116 (21): 4800.

https://doi.org/10.1182/blood.V116.21.4800.4800

Published: 2010

Journal Articles

Autotransplants for Multiple Myeloma (MM) – An Update of the Arkansas Experience Since 1989 In Almost 4000 Patients with Special Emphasis on Third and Further Transplants.

Bijay Nair, MD, MPH, Elias J. Anaissie, MD, Sarah Waheed, MD, Yazan Alsayed, MD, Rachael Sexton, Nathan Petty, Frits van Rhee, MD, PhD, Antje Hoering, PhD, Bart Barlogie, MD, PhD

Blood (2010) 116 (21): 1352.

https://doi.org/10.1182/blood.V116.21.1352.1352

Published: 2010

Journal Articles

Analysis of Serial Body Height Measurements In Total Therapy 2 (TT2, Control v Thalidomide Arm) and Total Therapy 3 (A: VTD Maintenance; B: VRD Maintenance) as a Guide to Overall Bone Health In Multiple Myeloma (MM)

Alan Mitchell, Antje Hoering, PhD, Frits van Rhee, MD, PhD, Elias J. Anaissie, MD, John Crowley, PhD, Bart Barlogie, MD, PhD

Blood (2010) 116 (21): 1354.

https://doi.org/10.1182/blood.V116.21.1354.1354

Published: 2010

Journal Articles

Pretreatment Platelet Count Predicts the Outcome of Invasive Aspergillosis among Myeloma Patients Undergoing Myelosuppressive Chemotherapy

Yue-Jin Wen, Weizhi Zhao, Monica Grazziutti, Wen Ling, Jeanette Lee, Susann M Szmania, Frits van Rhee, Bart Barlogie, Elias J. Anaissie

Blood (2008) 112 (11): 4353.

https://doi.org/10.1182/blood.V112.11.4353.4353

Published: 2008

Journal Articles

Deficiency of Mannose-Binding Lectin Is a Risk Factor for Invasive Pulmonary Aspergillosis in Patients with Multiple Myeloma: An Analysis of 482 Patients

Elias J. Anaissie, MD, Wei-zhi Zhao, Yue-Jin Wen, Monica Grazziutti, Wen Ling, Jeanette Lee, Frits van Rhee, Bart Barlogie

Blood (2008) 112 (11): 667.

https://doi.org/10.1182/blood.V112.11.667.667

Published: 2008

Journal Articles

Ninety Percent Sustained Complete Response (CR) Rate Projected 4 Years after Onset of CR in Gene Expression Profiling (GEP)-Defined Low-Risk Multiple Myeloma (MM) Treated with Total Therapy 3 (TT3): Basis for GEP-Risk-Adapted TT4 and TT5

Bart Barlogie, MD, PhD, Elias J. Anaissie, MD, John D. Shaughnessy, Jr., PhD, Frits van Rhee, MD, PhD, Mauricio Pineda-Roman, MD, Jeff Haessler, MD, Klaus A. Hollmig, MD, Yazan Alsayed, MD, Sarah Waheed, MD, Monica Graziutti, MD, Elias Kiwan, MD, John Crowley, PhD

Blood (2008) 112 (11): 162.

https://doi.org/10.1182/blood.V112.11.162.162

Published: 2008

Journal Articles

Monitoring Immune Function in the Allogeneic Transplant Recipient: Predicting Graft vs Host Disease (GvHD) and Infection.

Elias J. Anaissie, MD, Jose A. Diaz, MD, Monica L. Grazziutti, MD, Marisa H. Miceli, MD, Michele Fox-Cottler, MD, Bart Barlogie, MD, Frits van Rhee, MD

Blood (2007) 110 (11): 1966.

https://doi.org/10.1182/blood.V110.11.1966.1966

Published: 2007

Journal Articles

Predicting Response to Therapy for Graft-vs-Host Disease (GvHD) with a Rapid Immune Function Assay.

Elias J. Anaissie, MD, Jose A. Diaz, MD, Monica L. Grazziutti, MD, Marisa H. Miceli, MD, Michele Fox-Cottler, MD, Bart Barlogie, MD, Frits van Rhee, MD

Blood (2007) 110 (11): 5012.

https://doi.org/10.1182/blood.V110.11.5012.5012

Published: 2007

Journal Articles

Outcome of Invasive Aspergillosis (IA) in 30 Patients with Hematological Cancer (Hem-Ca): Immunity Is (Almost) Everything.

Marisa H. Miceli, MD, Monica L. Grazziutti, MD, Gail L. Woods, MD, Jose A. Diaz, MD, Somashekar G. Krishna, MD, Elias N. Kiwan, MD, Nayyar Syed, MD, Bart Barlogie, MD, PHD, Elias J. Anaissie, MD

Blood (2006) 108 (11): 5314.

https://doi.org/10.1182/blood.V108.11.5314.5314

Published: 2006

NARROW

Cullin-1 Controls The Clinical and Cellular response to Bortezomib Through NF-Kb Pathway Activation In Myeloma

Autophagy Is Uncoupled From ATG5-Dependent Apoptosis in Cells Resistant To Proteasome Inhibition

Chemotherapy-Induced Oral Mucositis: 11 SNPs Implicated In GWAS Of 972 Patients With Multiple Myeloma

Weight Loss, CD-34 Cell Dose and Melphalan Dose More Than 5 Mg/Kg Independently Predicted Severe Complications in Patients with Myeloma Undergoing Transplant.

Deregulated Cellular Iron Metabolism Factors Mediate Iron Overload in Myeloma Cells and Osteoclasts, and Promote Myeloma Growth and Bone Disease,

Low Expression of Nuclear Glucocorticoid Receptor Gene NR3C1 in Newly Diagnosed Myeloma Correlates with Inferior Prognosis and Is Rescued by Thalidomide

Jumping Translocations 1q12 Contribute to Copy Number (CN) Alterations in Multiple Myeloma (MM): Unexpected Focal Amplifications of Receptor Chromosomes (RC)

The Immature Reticulocyte Fraction Predicts Marrow Recovery and Can Obviate the Need for Bone Marrow Examination in Persistently Neutropenic Cancer Patients

Pacmed Salvage Therapy for Advanced High-Risk Multiple Myeloma (AHRMM)

Total Therapy 2 (TT2) for Multiple Myeloma (MM): Contributions to Survival Outcomes of Dosing of Thalidomide (T), Dexamethasone (D) and Interferon (I) Maintenance Components.

Comparing Toxicities and Survival Outcomes with Total Therapy 4 (TT4) for 70-Gene (R70)-Defined Low-Risk Multiple Myeloma (MM) to Results Obtained with Total Therapy 3 Protocols TT3A and TT3B

Super (S)-Beam for Advanced and Refractory Multiple Myeloma (ARMM)

Autotransplants for Multiple Myeloma (MM) – An Update of the Arkansas Experience Since 1989 In Almost 4000 Patients with Special Emphasis on Third and Further Transplants.

Analysis of Serial Body Height Measurements In Total Therapy 2 (TT2, Control v Thalidomide Arm) and Total Therapy 3 (A: VTD Maintenance; B: VRD Maintenance) as a Guide to Overall Bone Health In Multiple Myeloma (MM)

Pretreatment Platelet Count Predicts the Outcome of Invasive Aspergillosis among Myeloma Patients Undergoing Myelosuppressive Chemotherapy

Deficiency of Mannose-Binding Lectin Is a Risk Factor for Invasive Pulmonary Aspergillosis in Patients with Multiple Myeloma: An Analysis of 482 Patients

Ninety Percent Sustained Complete Response (CR) Rate Projected 4 Years after Onset of CR in Gene Expression Profiling (GEP)-Defined Low-Risk Multiple Myeloma (MM) Treated with Total Therapy 3 (TT3): Basis for GEP-Risk-Adapted TT4 and TT5

Monitoring Immune Function in the Allogeneic Transplant Recipient: Predicting Graft vs Host Disease (GvHD) and Infection.

Predicting Response to Therapy for Graft-vs-Host Disease (GvHD) with a Rapid Immune Function Assay.

Outcome of Invasive Aspergillosis (IA) in 30 Patients with Hematological Cancer (Hem-Ca): Immunity Is (Almost) Everything.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only